REVEFENACIN

Pre-Launch

revefenacin

Viatris

ANDAINHALATIONSOLUTION

Lifecycle

Pre-Launch

Clinical Trials

Data completeness

2/8 — Basic

REVEFENACIN (revefenacin) by Viatris is long-acting muscarinic antagonist, which is often referred to as an anticholinergic.

Drug data last refreshed 6h ago

Mechanism of Action

long-acting muscarinic antagonist, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (7)

NCT07721922Phase 4Not Yet Recruiting

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

Started Sep 2026

280 enrolled

COPD Exacerbation

NCT05046795Phase 3Completed

Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD)

Started Nov 2021

258 enrolled

COPD

NCT05207111Phase 1Completed

Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution

Started Sep 2021

24 enrolled

Healthy Volunteers Bioavailability Study

NCT04655170Phase 4Completed

Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD

Started Dec 2020

60 enrolled

COPD Exacerbation

NCT04315558Phase 2Completed

Revefenacin in Acute Respiratory Insufficiency in COPD

Started Nov 2020

21 enrolled

COPDAcute Respiratory Failure

Worked on REVEFENACIN at Viatris? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.